k141_206342_9	SARG|gb|AJD73064.1|ARO:3001301|RlmA(II)	33.5	251	257	282	2.39e-56	181
k141_206342_9	megares|MEG_4107|Drugs|MLS|23S_rRNA_methyltransferases|MYRA_1	30.8	237	257	283	3.53e-27	105
k141_136118_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.4	225	241	219	1.68e-42	142
k141_136118_5	CARD|gb|AAG06465.1|ARO:3005063|cprR	38.1	231	241	223	1.12e-37	130
k141_136118_5	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	35.7	227	241	225	3.32e-37	129
k141_136118_5	CARD|gb|AAC73788.1|ARO:3003841|kdpE	35.7	227	241	225	3.32e-37	129
k141_136118_5	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.5	234	241	232	3.98e-37	129
k141_136118_5	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	32.5	234	241	232	3.98e-37	129
k141_136118_5	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.2	229	241	228	1.00e-36	128
k141_136118_5	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	32.1	234	241	231	3.62e-34	121
k141_136118_5	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.1	234	241	231	3.62e-34	121
k141_136118_5	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	30.9	233	241	229	2.67e-33	119
k141_136118_6	SARG|gb|CAA03986.1|ARO:3000343|tap	26.8	440	456	409	7.78e-35	133
k141_236598_6	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	41.2	313	330	337	7.97e-77	238
k141_236598_6	SARG|KF478993.1.gene2.p01	38.9	321	330	350	4.67e-76	236
k141_236598_6	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	40.1	322	330	343	1.07e-75	235
k141_236598_6	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	42.4	290	330	351	1.92e-75	234
k141_236598_6	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	41.0	312	330	348	3.51e-75	234
k141_236598_6	SARG|gi|552942232|ref|WP_023043160.1|	41.9	313	330	323	1.50e-73	229
k141_236598_6	SARG|AY082011.1.gene6.p01	41.5	313	330	323	1.19e-72	226
k141_236598_6	SARG|AAR37059	41.0	315	330	323	2.38e-72	226
k141_236598_6	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	39.9	313	330	323	1.34e-71	224
k141_236598_6	SARG|gi|740152780|ref|WP_037997109.1|	40.7	312	330	322	2.59e-71	223
k141_236598_11	SARG|YP_001571041	38.7	225	254	648	1.48e-37	138
k141_236598_11	SARG|gi|960873409|ref|WP_058345546.1|	38.7	225	254	648	1.48e-37	138
k141_236598_11	SARG|gi|740610794|ref|WP_038396317.1|	38.7	225	254	648	2.04e-37	137
k141_236598_11	SARG|gi|923061916|ref|WP_053445667.1|	38.6	233	254	648	1.36e-36	135
k141_236598_11	SARG|gi|746482713|ref|WP_039520502.1|	38.2	225	254	648	2.55e-36	134
k141_236598_11	SARG|YP_002044935	38.2	233	254	648	3.49e-36	134
k141_236598_11	SARG|gi|835666879|ref|WP_047606339.1|	38.2	233	254	648	3.49e-36	134
k141_236598_11	SARG|gi|446048048|ref|WP_000125903.1|	38.2	225	254	648	3.49e-36	134
k141_236598_11	SARG|gi|555254264|ref|WP_023237471.1|	38.2	233	254	648	3.49e-36	134
k141_236598_11	SARG|gi|959101689|ref|WP_058107049.1|	38.2	233	254	648	3.49e-36	134
k141_236598_18	SARG|gb|APB03219.1|ARO:3003986|TaeA	23.8	269	306	648	8.20e-09	55.5
k141_171243_10	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	35.0	143	397	639	1.07e-13	71.6
k141_141665_3	SARG|gi|921979807|ref|WP_053271336.1|	31.1	238	369	648	4.52e-17	81.6
k141_141665_3	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.1	199	369	258	4.37e-14	70.5
k141_111414_17	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.3	244	476	451	1.06e-22	99.4
k141_111414_17	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	25.4	268	476	392	1.68e-16	80.1
k141_111414_17	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.1	242	476	370	2.58e-16	79.3
k141_111414_17	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	245	476	381	1.63e-14	73.9
k141_111414_17	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	245	476	381	1.63e-14	73.9
k141_111414_17	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.1	237	476	365	3.52e-14	72.8
k141_111414_17	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.5	235	476	381	6.93e-14	72.0
k141_111414_17	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.5	235	476	381	6.93e-14	72.0
k141_111414_18	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	43.8	224	238	228	1.24e-49	161
k141_111414_18	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	38.8	219	238	225	7.24e-45	149
k141_111414_18	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.2	227	238	219	1.93e-43	145
k141_111414_18	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.4	227	238	231	1.51e-42	143
k141_111414_18	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.6	226	238	232	6.14e-42	141
k141_111414_18	CARD|gb|AAG05188.1|ARO:3005068|ParR	36.9	222	238	235	1.16e-39	135
k141_111414_18	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	35.8	240	238	252	3.92e-38	132
k141_111414_18	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.9	222	238	229	1.20e-37	130
k141_111414_18	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.5	226	238	231	1.97e-36	127
k141_111414_18	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.5	226	238	231	2.77e-36	127
k141_111414_19	SARG|gi|917172177|ref|WP_051778889.1|	35.2	88	104	620	3.41e-10	54.3
k141_111414_19	SARG|gi|919568551|ref|WP_052871170.1|	35.2	88	104	620	3.41e-10	54.3
k141_111414_19	SARG|gi|917229923|ref|WP_051836635.1|	35.2	88	104	620	3.41e-10	54.3
k141_111414_19	SARG|gi|921231571|ref|WP_053176464.1|	35.2	88	104	620	3.41e-10	54.3
k141_111414_19	SARG|gi|917203192|ref|WP_051809904.1|	35.2	88	104	620	8.67e-10	53.1
k141_111414_19	SARG|gi|926356413|ref|WP_053687351.1|	35.2	88	104	620	8.67e-10	53.1
k141_111414_19	SARG|gi|926345639|ref|WP_053677539.1|	35.2	88	104	620	8.67e-10	53.1
k141_111414_19	SARG|gi|799286378|ref|WP_045936958.1|	35.2	88	104	620	8.67e-10	53.1
k141_111414_19	SARG|gi|917127754|ref|WP_051734466.1|	35.2	88	104	620	8.67e-10	53.1
k141_111414_19	SARG|gi|926376632|ref|WP_053705806.1|	35.2	88	104	620	8.67e-10	53.1
k141_10953_11	SARG|gi|746253210|ref|WP_039301529.1|	30.9	262	251	648	1.90e-29	115
k141_10953_11	SARG|gi|746243059|ref|WP_039291473.1|	30.3	261	251	648	2.59e-29	114
k141_10953_11	SARG|gi|1001720867|ref|WP_061274204.1|	34.6	185	251	648	4.80e-29	114
k141_10953_11	SARG|gi|495736522|ref|WP_008461101.1|	34.6	185	251	648	6.54e-29	113
k141_10953_11	SARG|gi|749017716|ref|WP_040076354.1|	31.5	260	251	646	8.87e-29	113
k141_10953_11	SARG|gi|751930065|ref|WP_041144773.1|	28.9	280	251	648	3.05e-28	111
k141_10953_11	SARG|gi|896325272|ref|WP_049294291.1|	28.8	243	251	648	4.16e-28	111
k141_10953_11	SARG|gi|696411918|ref|WP_032982657.1|	29.7	259	251	647	7.68e-28	110
k141_10953_11	SARG|gi|742378414|ref|WP_038857601.1|	31.6	263	251	647	1.42e-27	109
k141_10953_11	SARG|gi|696402390|ref|WP_032974230.1|	29.7	259	251	647	1.93e-27	109
k141_127086_5	SARG|gb|BAE15963.1|ARO:3002868|dfrG	36.5	170	205	165	1.03e-29	107
k141_127086_5	NCBI|WP_012779617.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	36.3	168	205	163	7.71e-29	104
k141_127086_5	SARG|gb|CBL80435.1|ARO:3002869|dfrK	34.7	167	205	163	1.09e-28	104
k141_127086_5	NCBI|WP_031775848.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	34.7	167	205	163	1.09e-28	104
k141_127086_5	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	30.8	169	205	164	2.09e-21	85.5
k141_127086_5	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	34.1	170	205	167	7.04e-19	79.0
k141_127086_5	SARG|gb|CAF31623.1|ARO:3005354|dfr22	33.5	155	205	165	2.72e-17	74.7
k141_127086_5	NCBI|WP_063844370.1|1|1|dfrA22|dfrA22|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA22|AMR|diaminopyrimidine	33.5	155	205	165	7.44e-17	73.6
k141_127086_5	SARG|CAX16467	32.9	155	205	165	1.45e-16	72.8
k141_127086_5	NCBI|WP_071846242.1|1|1|dfrA33|dfrA33|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA33|AMR|diaminopyrimidine	32.9	155	205	165	2.03e-16	72.4
k141_132067_11	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.8	119	350	229	7.37e-15	72.0
k141_132067_11	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.4	153	350	231	1.04e-12	65.9
k141_132067_11	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.4	153	350	231	1.42e-12	65.5
k141_132067_11	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.4	153	350	231	1.42e-12	65.5
k141_132067_11	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.1	153	350	231	2.61e-12	64.7
k141_132067_11	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.1	127	350	230	9.80e-11	60.1
k141_132067_11	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.9	162	350	228	4.32e-10	58.2
k141_132067_11	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	32.8	122	350	239	8.88e-10	57.4
k141_132067_11	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	28.7	136	350	232	2.73e-09	55.8
k141_132067_11	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	28.7	136	350	232	2.73e-09	55.8
k141_132067_13	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.5	389	853	1197	1.05e-37	151
k141_132067_29	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	49.1	159	157	159	9.12e-47	148
k141_31748_4	SARG|gb|BAI83385.1|ARO:3003440|mecB	25.9	293	939	674	7.09e-09	58.5
k141_31748_4	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	25.9	293	939	674	9.32e-09	58.2
k141_31748_5	CARD|gb|WKR28567.1|ARO:3007678|IreK	34.0	618	648	718	4.23e-88	288
k141_31748_10	SARG|gb|CDO61516.1|ARO:3003949|efrB	48.3	348	642	362	1.62e-98	305
k141_31748_10	SARG|gb|AAK76136.1|ARO:3000025|patB	32.9	590	642	588	5.60e-97	308
k141_31748_10	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.9	491	642	664	1.06e-95	307
k141_31748_10	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.5	590	642	579	1.15e-79	262
k141_31748_10	SARG|gi|948137056|ref|WP_056795395.1|	32.3	588	642	602	1.41e-79	263
k141_31748_10	SARG|gi|493394434|ref|WP_006350564.1|	32.1	595	642	602	5.54e-78	258
k141_31748_10	SARG|gi|517381192|ref|WP_018555350.1|	34.5	504	642	602	7.73e-78	258
k141_31748_10	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.7	590	642	579	1.24e-77	257
k141_31748_10	SARG|AF170880.4.gene1.p01	32.3	585	642	615	2.02e-77	257
k141_31748_10	SARG|gi|558888514|ref|WP_023543283.1|	34.3	502	642	615	3.92e-77	256
k141_31748_11	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.4	597	613	575	6.68e-117	358
k141_31748_11	SARG|gb|AAK76137.1|ARO:3000024|patA	32.2	597	613	564	2.25e-90	289
k141_31748_11	SARG|gi|748767925|ref|WP_040019608.1|	43.5	239	613	623	2.28e-52	189
k141_31748_11	SARG|gi|943909899|ref|WP_055545300.1|	28.4	610	613	601	4.25e-52	187
k141_31748_11	SARG|gi|1011969930|ref|WP_062776015.1|	27.8	608	613	601	5.84e-52	187
k141_31748_11	SARG|gi|764446018|ref|WP_044369325.1|	28.0	604	613	605	1.62e-51	186
k141_31748_11	SARG|gi|558888514|ref|WP_023543283.1|	43.4	228	613	615	1.88e-51	186
k141_31748_11	SARG|gi|501350226|ref|WP_012381861.1|	43.2	229	613	603	2.97e-51	185
k141_31748_11	SARG|gi|695865802|ref|WP_032778631.1|	42.4	229	613	605	3.06e-51	185
k141_31748_11	SARG|gi|663330365|ref|WP_030329892.1|	28.1	602	613	607	3.15e-51	185
k141_31748_14	CARD|gb|VWQ00850.1|ARO:3003843|leuO	42.4	66	330	314	1.09e-06	48.5
k141_31748_27	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	35.7	224	319	293	6.23e-30	114
k141_31748_27	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.2	218	319	307	3.88e-24	99.0
k141_31748_27	SARG|gi|542061059|gb|ERI11611.1|	31.2	218	319	316	5.83e-23	95.9
k141_31748_27	SARG|gi|500194536|ref|WP_011867743.1|	31.2	218	319	306	1.81e-22	94.4
k141_31748_27	SARG|YP_001176128	27.6	228	319	646	6.82e-12	65.1
k141_31748_27	SARG|gi|974588181|ref|WP_059178476.1|	26.3	228	319	646	2.18e-11	63.5
k141_31748_27	SARG|gb|AVI44920.1|ARO:3004470|poxtA	29.4	170	319	542	1.12e-07	52.0
k141_31748_27	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	29.4	170	319	544	1.13e-07	52.0
k141_31748_39	SARG|gi|772774655|ref|WP_045322518.1|	33.9	598	591	620	1.96e-99	314
k141_31748_39	SARG|gi|664042835|ref|WP_030582300.1|	33.3	577	591	604	3.58e-99	313
k141_31748_39	SARG|gi|695842130|ref|WP_032755430.1|	32.8	577	591	603	1.36e-98	311
k141_31748_39	SARG|gi|948137056|ref|WP_056795395.1|	33.3	577	591	602	2.61e-98	310
k141_31748_39	SARG|gi|799286378|ref|WP_045936958.1|	33.8	598	591	620	2.97e-98	311
k141_31748_39	SARG|gi|926294973|ref|WP_053631154.1|	33.8	598	591	620	2.97e-98	311
k141_31748_39	SARG|gi|944009777|ref|WP_055601444.1|	33.3	594	591	628	3.64e-98	311
k141_31748_39	SARG|gi|764446018|ref|WP_044369325.1|	33.3	577	591	605	3.97e-98	310
k141_31748_39	SARG|gi|926356413|ref|WP_053687351.1|	33.8	598	591	620	4.17e-98	310
k141_31748_39	SARG|gi|926345639|ref|WP_053677539.1|	33.8	598	591	620	4.17e-98	310
k141_31748_59	SARG|gi|726981187|ref|WP_033585865.1|	31.4	344	320	340	3.40e-39	140
k141_31748_59	SARG|gi|726976857|ref|WP_033582037.1|	31.4	344	320	340	6.65e-39	139
k141_31748_59	SARG|gi|749574464|ref|WP_040203371.1|	32.0	344	320	343	7.09e-39	139
k141_31748_59	SARG|ACP19236	31.4	344	320	343	9.91e-39	139
k141_31748_59	SARG|NP_878016	31.1	344	320	343	2.70e-38	137
k141_31748_59	SARG|gi|309385870|gb|ADO66795.1|	31.1	344	320	359	3.75e-38	137
k141_31748_59	SARG|gi|751653785|ref|WP_041120633.1|	33.6	283	320	343	5.28e-38	137
k141_31748_59	SARG|gi|447002588|ref|WP_001079844.1|	31.1	344	320	343	7.37e-38	136
k141_31748_59	NCBI|WP_011029110.1|1|1|vanA-Sc|vanA-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanA-Sc|AMR|glycopeptide	35.7	269	320	346	2.14e-37	135
k141_31748_59	megares|MEG_7340|Drugs|Glycopeptide|VanA-type_resistance_protein|VANA_1	35.7	269	320	346	2.14e-37	135
k141_31748_60	SARG|gb|AGZ55247.1|ARO:3002814|clbA	35.5	332	349	349	1.75e-58	191
k141_31748_60	SARG|VXQ21601.1	35.5	332	349	344	3.96e-55	182
k141_31748_60	SARG|gb|ACX65640.1|ARO:3003907|cipA	33.2	334	349	346	8.96e-54	179
k141_31748_74	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	42.5	701	675	703	4.33e-165	489
k141_6504_3	SARG|gi|921979807|ref|WP_053271336.1|	28.6	220	238	648	3.16e-19	85.1
k141_6504_3	SARG|gb|AAV85982.1|ARO:3000535|macB	25.9	220	238	644	4.84e-18	81.6
k141_6504_3	SARG|gb|AAK76137.1|ARO:3000024|patA	27.1	218	238	564	8.84e-15	72.0
k141_6504_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.1	211	238	664	2.82e-12	64.7
k141_6504_3	SARG|gb|AEA37904.1|ARO:3003112|lsaC	26.1	203	238	492	6.76e-11	60.5
k141_6504_3	SARG|gb|AAK76136.1|ARO:3000025|patB	23.2	211	238	588	7.24e-11	60.5
k141_6504_3	SARG|AXF35727.1	26.8	179	238	497	6.23e-08	51.6
k141_6504_3	SARG|gb|CDO61516.1|ARO:3003949|efrB	26.6	158	238	362	9.62e-08	50.8
k141_6504_3	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	162	238	655	7.13e-07	48.5
k141_6504_3	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	162	238	655	7.13e-07	48.5
k141_6504_4	SARG|gb|AAC75271.1|ARO:3003952|yojI	28.1	196	284	547	1.32e-11	63.5
k141_6504_24	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	29.3	512	507	505	6.04e-71	233
k141_6504_24	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	29.1	499	507	504	2.52e-68	226
k141_6504_24	SARG|M57437.gene.p01	27.4	565	507	548	3.82e-29	119
k141_6504_24	SARG|X63451.gene.p01	24.9	554	507	550	7.18e-22	97.8
k141_6504_24	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	24.9	554	507	550	7.18e-22	97.8
k141_6504_24	SARG|gb|CBL58195.1|ARO:3002831|vgaC	27.6	482	507	522	3.59e-18	86.3
k141_6504_24	SARG|gb|APB03219.1|ARO:3003986|TaeA	33.7	190	507	648	2.46e-16	80.9
k141_6504_24	SARG|gb|AEO25219.1|ARO:3004651|lin	31.8	176	507	523	4.39e-15	76.6
k141_6504_24	SARG|DAC81085.1	31.5	178	507	486	1.64e-14	74.7
k141_6504_24	SARG|FR772051.1.gene9.p01	33.9	171	507	524	9.83e-14	72.4
k141_6504_63	SARG|gi|851922185|ref|WP_048218206.1|	40.9	225	297	648	9.82e-41	148
k141_6504_63	SARG|gi|949718947|ref|WP_057063453.1|	40.9	225	297	648	9.82e-41	148
k141_6504_63	SARG|gi|696375069|ref|WP_032949617.1|	40.9	225	297	648	9.82e-41	148
k141_6504_63	SARG|gi|489127020|ref|WP_003036815.1|	40.9	225	297	648	9.82e-41	148
k141_6504_63	SARG|gi|1045891604|ref|WP_065554100.1|	40.9	225	297	648	1.35e-40	148
k141_6504_63	SARG|gi|507082903|ref|WP_016153652.1|	40.9	225	297	648	1.35e-40	148
k141_6504_63	SARG|gi|851913025|ref|WP_048215946.1|	40.9	225	297	648	1.86e-40	147
k141_6504_63	SARG|gi|740856590|ref|WP_038641842.1|	42.3	208	297	648	1.86e-40	147
k141_6504_63	SARG|gi|507086196|ref|WP_016156937.1|	40.9	225	297	648	1.86e-40	147
k141_6504_63	SARG|gi|489930965|ref|WP_003834285.1|	40.9	225	297	648	1.86e-40	147
k141_167567_5	SARG|gb|AAK76137.1|ARO:3000024|patA	27.4	208	265	564	3.30e-18	82.8
k141_167567_15	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	56.9	1136	1166	1162	0.0	1238
k141_167567_15	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	55.9	1151	1166	1186	0.0	1217
k141_167567_15	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	55.9	1151	1166	1186	0.0	1217
k141_167567_19	SARG|CAA37477	50.0	128	140	663	7.84e-34	123
k141_167567_19	SARG|NP_348076	47.7	128	140	652	1.77e-32	119
k141_167567_19	SARG|FN594949.1.gene24.p01	46.9	128	140	640	4.44e-32	118
k141_167567_19	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	46.9	128	140	640	4.44e-32	118
k141_167567_19	SARG|ABV82118	46.9	128	140	639	6.06e-32	117
k141_167567_19	SARG|ZP_03989103	46.9	128	140	639	6.06e-32	117
k141_167567_19	SARG|ABV82120	46.9	128	140	639	6.06e-32	117
k141_167567_19	megares|MEG_7167|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	46.9	128	140	639	1.14e-31	117
k141_167567_19	SARG|ACI02041	46.9	128	140	639	1.56e-31	116
k141_167567_19	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	46.9	128	140	629	2.08e-31	116
k141_92158_16	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	42.6	223	225	223	9.22e-56	176
k141_92158_16	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.5	222	225	229	2.89e-38	131
k141_92158_16	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.3	228	225	231	2.07e-35	124
k141_92158_16	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.3	228	225	231	8.13e-35	122
k141_92158_16	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	32.9	231	225	231	4.50e-34	120
k141_92158_16	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.9	231	225	231	4.50e-34	120
k141_92158_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.6	205	225	228	5.87e-34	120
k141_92158_16	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.5	206	225	235	7.63e-33	117
k141_92158_16	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	31.3	230	225	232	9.98e-33	117
k141_92158_16	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	31.3	230	225	232	9.98e-33	117
k141_92158_17	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	33.0	300	355	341	9.00e-50	169
k141_92158_20	SARG|ZP_03949893	49.5	309	340	288	5.90e-97	288
k141_92158_20	SARG|ZP_04433866	49.5	309	340	288	1.68e-96	286
k141_92158_20	SARG|ZP_03984017	49.5	309	340	288	1.68e-96	286
k141_92158_20	SARG|ZP_03945515	49.8	315	340	291	7.88e-93	277
k141_92158_20	SARG|ZP_04528247	49.2	313	340	279	1.39e-90	271
k141_92158_20	SARG|YP_002929946	48.2	309	340	282	2.28e-87	263
k141_92158_20	SARG|ZP_03941859	46.1	310	340	288	4.09e-84	255
k141_92158_20	SARG|ZP_03938934	46.1	310	340	288	4.09e-84	255
k141_92158_20	SARG|ZP_03958019	47.0	317	340	317	2.97e-80	246
k141_92158_20	SARG|YP_002937728	47.0	319	340	289	2.82e-79	243
k141_92158_35	SARG|gi|746243059|ref|WP_039291473.1|	44.1	220	234	648	3.80e-51	174
k141_92158_35	SARG|gi|495736522|ref|WP_008461101.1|	44.1	220	234	648	5.23e-50	171
k141_92158_35	SARG|gi|746253210|ref|WP_039301529.1|	44.1	220	234	648	5.23e-50	171
k141_92158_35	SARG|gi|1001720867|ref|WP_061274204.1|	43.6	220	234	648	7.26e-50	171
k141_92158_35	SARG|gi|895865878|ref|WP_048974758.1|	42.3	220	234	646	9.85e-50	171
k141_92158_35	SARG|gb|AAV85982.1|ARO:3000535|macB	38.6	236	234	644	4.95e-49	169
k141_92158_35	SARG|gi|694064328|ref|WP_032410816.1|	41.4	220	234	646	2.59e-48	167
k141_92158_35	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.9	225	234	575	6.82e-19	84.0
k141_92158_35	SARG|gi|948137056|ref|WP_056795395.1|	31.8	233	234	602	2.34e-18	82.4
k141_92158_35	SARG|gi|648667297|ref|WP_026359044.1|	31.8	236	234	605	5.84e-18	81.3
k141_92158_38	SARG|CP001581.1.gene725.p01	42.3	454	488	477	2.22e-109	332
k141_92158_38	SARG|NP_733568	29.2	401	488	536	3.23e-51	181
k141_92158_38	SARG|YP_002196817	28.8	437	488	536	5.95e-49	175
k141_92158_38	SARG|JQ768046.1.gene8.p1	30.0	434	488	559	1.75e-43	160
k141_92158_38	SARG|CP001918.1.gene3442.p01	30.1	438	488	457	3.39e-43	157
k141_92158_38	SARG|gb|BAA11237.1|ARO:3000254|emrY	28.0	439	488	512	3.03e-42	156
k141_92158_38	SARG|gi|780037362|ref|WP_045446599.1|	28.0	422	488	512	1.09e-41	154
k141_92158_38	SARG|YP_001419960	25.6	399	488	510	2.01e-41	154
k141_92158_38	SARG|gi|745784185|ref|WP_039077609.1|	28.4	422	488	512	3.92e-41	153
k141_92158_38	SARG|gi|817112355|ref|WP_046485582.1|	27.7	422	488	512	7.42e-41	152
k141_92158_43	SARG|gb|AAV85982.1|ARO:3000535|macB	40.4	223	254	644	6.98e-41	147
k141_92158_43	SARG|gi|740610794|ref|WP_038396317.1|	37.6	242	254	648	3.04e-38	140
k141_92158_43	SARG|gi|495736522|ref|WP_008461101.1|	37.3	228	254	648	1.08e-37	138
k141_92158_43	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.5	220	254	579	9.96e-17	78.2
k141_92158_43	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	29.0	217	254	579	1.11e-15	75.1
k141_92158_70	SARG|BBJ25230.1	31.0	203	295	263	2.05e-13	67.8
k141_92158_74	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	54.3	232	238	232	8.17e-90	263
k141_92158_74	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	54.3	232	238	232	8.17e-90	263
k141_92158_74	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	52.6	234	238	233	2.46e-84	249
k141_92158_74	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	51.1	233	238	231	4.35e-82	244
k141_92158_74	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	50.6	233	238	235	4.96e-82	244
k141_92158_74	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	50.6	233	238	231	8.74e-82	243
k141_92158_74	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	51.9	233	238	231	1.24e-81	243
k141_92158_74	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	51.9	233	238	231	1.24e-81	243
k141_92158_74	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	50.2	233	238	231	5.01e-81	241
k141_92158_74	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	52.8	233	238	232	2.09e-80	239
k141_92158_75	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	58.3	235	475	392	1.12e-85	267
k141_92158_75	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	56.6	221	475	386	2.89e-77	245
k141_92158_75	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	56.6	221	475	386	2.89e-77	245
k141_92158_75	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	56.6	221	475	388	3.06e-77	245
k141_92158_75	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	56.6	221	475	388	3.06e-77	245
k141_92158_75	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	55.2	221	475	384	7.62e-77	244
k141_92158_75	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	55.2	221	475	384	7.62e-77	244
k141_92158_75	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	55.2	221	475	386	8.07e-77	244
k141_92158_75	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	55.2	221	475	386	8.07e-77	244
k141_92158_75	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	55.2	221	475	382	2.82e-76	243
k141_2612_12	megares|MEG_3790|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	24.6	605	682	666	3.84e-25	109
k141_2612_12	SARG|gi|446643957|ref|WP_000721303.1|	23.9	615	682	668	5.12e-25	109
k141_2612_12	SARG|gi|686330880|ref|WP_031879536.1|	23.9	615	682	668	5.12e-25	109
k141_2612_12	SARG|gi|686404991|ref|WP_031911502.1|	23.9	589	682	668	5.12e-25	109
k141_2612_12	SARG|gi|2791908|emb|CAA73538.1|	24.5	605	682	666	6.75e-25	108
k141_2612_12	SARG|gi|916178542|ref|WP_050963202.1|	24.1	589	682	668	6.79e-25	108
k141_2612_12	SARG|gi|446643961|ref|WP_000721307.1|	23.9	589	682	668	6.79e-25	108
k141_2612_12	SARG|gi|727743592|ref|WP_033859381.1|	23.9	589	682	668	6.79e-25	108
k141_2612_12	SARG|gi|686322767|ref|WP_031876626.1|	23.9	589	682	668	6.79e-25	108
k141_2612_12	SARG|gi|686291256|ref|WP_031861724.1|	23.9	589	682	668	6.79e-25	108
k141_227946_7	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	35.6	334	333	343	2.02e-57	188
k141_227946_7	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	34.5	328	333	325	1.18e-50	170
k141_227946_7	SARG|gb|AAA26793|ARO:3003748|oleC	34.5	328	333	325	2.33e-50	169
k141_227946_7	SARG|gb|AAR96051.1|ARO:3002894|otrC	30.1	342	333	351	1.29e-32	123
k141_227946_7	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	30.1	342	333	351	1.80e-32	122
k141_227946_7	SARG|gb|APB03219.1|ARO:3003986|TaeA	22.3	238	333	648	7.80e-09	55.8
k141_227946_17	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.5	885	912	885	3.24e-121	388
k141_227946_17	CARD|gb|AAC75429.1|ARO:3000833|evgS	25.1	251	912	1197	8.96e-16	81.3
k141_227946_18	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	45.1	224	238	225	9.92e-62	192
k141_227946_18	CARD|gb|AAC73788.1|ARO:3003841|kdpE	45.1	224	238	225	9.92e-62	192
k141_227946_18	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.4	228	238	228	2.22e-47	155
k141_227946_18	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.8	224	238	231	7.65e-46	151
k141_227946_18	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.7	223	238	219	9.66e-44	145
k141_227946_18	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.1	232	238	233	1.77e-41	140
k141_227946_18	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.8	230	238	232	2.43e-41	140
k141_227946_18	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.8	230	238	232	2.43e-41	140
k141_227946_18	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.6	224	238	232	3.43e-41	139
k141_227946_18	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.8	233	238	235	2.07e-40	137
k141_227946_21	SARG|gb|APB03219.1|ARO:3003986|TaeA	35.1	544	629	648	2.42e-97	310
k141_227946_21	SARG|gb|NP_388442.1|ARO:3004476|vmlR	30.2	514	629	547	2.75e-57	201
k141_227946_21	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	29.7	515	629	485	3.29e-51	183
k141_227946_21	SARG|gb|QNR09092.1|ARO:3007042|msr(G)	28.4	510	629	485	1.56e-49	178
k141_227946_21	SARG|AAA50325	30.4	530	629	569	2.64e-49	179
k141_227946_21	SARG|AY004350.gene.p01	27.4	525	629	492	1.15e-47	173
k141_227946_21	SARG|FR772051.1.gene9.p01	28.2	525	629	524	2.78e-47	173
k141_227946_21	SARG|gi|488231473|ref|WP_002302681.1|	27.3	527	629	492	2.99e-47	172
k141_227946_21	SARG|gi|488216250|ref|WP_002287458.1|	27.0	525	629	492	2.99e-47	172
k141_227946_21	SARG|gi|488243106|ref|WP_002314314.1|	27.7	520	629	492	1.07e-46	171
k141_227946_35	SARG|gi|936194420|ref|WP_054528571.1|	35.5	231	261	648	3.87e-35	131
k141_227946_35	SARG|gi|740856590|ref|WP_038641842.1|	36.4	231	261	648	3.87e-35	131
k141_227946_35	SARG|gi|491270241|ref|WP_005128370.1|	36.4	231	261	648	5.30e-35	131
k141_227946_35	SARG|gi|851913025|ref|WP_048215946.1|	36.4	231	261	648	5.30e-35	131
k141_227946_35	SARG|YP_002850060	36.4	231	261	648	5.30e-35	131
k141_227946_35	SARG|gi|851902043|ref|WP_048212057.1|	36.4	231	261	648	5.30e-35	131
k141_227946_35	SARG|gi|489930965|ref|WP_003834285.1|	36.4	231	261	648	5.30e-35	131
k141_227946_35	SARG|gi|992380339|ref|WP_061067665.1|	36.4	231	261	648	5.30e-35	131
k141_227946_35	SARG|gi|493734654|ref|WP_006683876.1|	36.3	234	261	648	5.30e-35	131
k141_227946_35	SARG|gi|754951242|ref|WP_042307417.1|	36.4	231	261	648	7.25e-35	130
k141_77216_19	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	34.5	475	483	481	4.73e-66	219
k141_77216_19	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	33.3	477	483	451	3.99e-62	208
k141_77216_19	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	32.8	473	483	451	2.14e-61	206
k141_77216_20	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	26.8	489	611	633	2.57e-28	119
k141_77216_20	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	24.6	488	611	665	8.98e-20	92.4
k141_77216_20	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	24.2	492	611	665	3.43e-18	87.4
k141_77216_20	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	24.5	493	611	665	2.42e-17	84.7
k141_77216_20	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	24.0	467	611	664	1.29e-16	82.4
k141_77216_20	SARG|gb|CCC86795.1|ARO:3001209|mecC	24.0	467	611	665	1.71e-16	82.0
k141_77216_20	SARG|gi|2791908|emb|CAA73538.1|	23.4	483	611	666	2.99e-16	81.3
k141_77216_20	megares|MEG_3792|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	23.2	483	611	666	2.77e-15	78.2
k141_77216_20	SARG|gb|AQX82857.1|ARO:3004185|mecD	23.7	482	611	678	7.90e-14	73.6
k141_77216_24	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	28.6	276	302	346	3.99e-16	76.6
k141_192776_9	SARG|gi|446048013|ref|WP_000125868.1|	31.4	239	676	648	6.31e-20	93.2
k141_192776_9	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	22.6	212	676	550	7.51e-10	60.8
k141_192776_10	SARG|gb|AAK76137.1|ARO:3000024|patA	29.7	209	274	564	3.88e-15	73.9
k141_192776_10	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.2	221	274	574	1.03e-13	69.7
k141_192776_30	SARG|gi|1032819400|ref|WP_064325534.1|	32.5	234	378	646	3.74e-27	112
k141_192776_30	SARG|gi|1028212610|ref|WP_063955653.1|	33.5	233	378	646	3.05e-26	109
k141_192776_30	SARG|gi|976152237|ref|WP_059310432.1|	33.5	233	378	646	4.11e-26	108
k141_192776_30	SARG|gi|1022675034|ref|WP_063431065.1|	33.5	233	378	646	4.11e-26	108
k141_192776_30	SARG|gi|779850732|ref|WP_045348329.1|	33.0	233	378	646	4.11e-26	108
k141_192776_30	SARG|gi|746243059|ref|WP_039291473.1|	33.8	234	378	648	4.12e-26	108
k141_192776_30	SARG|gi|751930065|ref|WP_041144773.1|	33.5	233	378	648	4.12e-26	108
k141_192776_30	SARG|gi|1022698495|ref|WP_063449190.1|	32.5	231	378	646	5.54e-26	108
k141_192776_30	SARG|gi|851931792|ref|WP_048222288.1|	33.5	233	378	646	5.54e-26	108
k141_192776_30	SARG|gi|981224618|ref|WP_059445588.1|	33.5	233	378	646	5.54e-26	108
k141_192776_31	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	23.1	229	341	574	2.54e-12	66.6
k141_83054_10	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.5	764	904	1024	8.20e-61	223
k141_83054_10	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.5	764	904	1024	8.20e-61	223
k141_83054_10	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.5	764	904	1024	1.48e-60	222
k141_83054_10	SARG|gb|CAA53189|ARO:3000521|mupA	24.5	764	904	1024	1.48e-60	222
k141_83054_10	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	23.5	839	904	1033	2.82e-60	221
k141_83054_10	SARG|gb|AEY83581|ARO:3000510|mupB	23.5	839	904	1033	2.82e-60	221
k141_38226_4	SARG|gi|542061059|gb|ERI11611.1|	38.4	211	324	316	7.65e-41	144
k141_38226_4	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	38.4	219	324	307	8.68e-41	143
k141_38226_4	SARG|gi|500194536|ref|WP_011867743.1|	37.9	211	324	306	6.78e-39	138
k141_38226_4	SARG|ABB80128	37.4	206	324	306	2.60e-38	137
k141_38226_4	SARG|gi|445996719|ref|WP_000074574.1|	36.7	215	324	309	5.46e-38	136
k141_38226_4	SARG|gi|488130770|ref|WP_002201978.1|	37.2	215	324	309	7.64e-38	135
k141_38226_4	SARG|gi|500448961|gb|EOP61695.1|	36.2	213	324	306	9.98e-38	135
k141_38226_4	SARG|gi|445996710|ref|WP_000074565.1|	36.7	215	324	309	2.09e-37	134
k141_38226_4	SARG|gi|500465078|gb|EOP76697.1|	36.2	213	324	306	2.73e-37	134
k141_38226_4	SARG|gi|1043490477|ref|WP_065382463.1|	36.3	215	324	309	2.92e-37	134
k141_38226_22	SARG|P42332	35.2	327	333	306	9.91e-65	206
k141_38226_22	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	35.2	327	333	306	9.91e-65	206
k141_38226_22	SARG|gi|510143239|gb|AGN36970.1|	35.2	327	333	313	1.21e-64	206
k141_38226_22	SARG|ABB80128	34.9	327	333	306	1.11e-63	203
k141_38226_22	SARG|AAD21213	34.9	327	333	306	1.56e-63	202
k141_38226_22	SARG|gi|488042066|ref|WP_002113463.1|	36.1	327	333	309	5.32e-62	199
k141_38226_22	SARG|gi|500448961|gb|EOP61695.1|	34.9	327	333	306	6.89e-62	198
k141_38226_22	SARG|gi|447057509|ref|WP_001134765.1|	36.1	327	333	309	1.49e-61	197
k141_38226_22	SARG|gi|500465078|gb|EOP76697.1|	34.5	328	333	306	1.94e-61	197
k141_38226_22	SARG|gi|445996719|ref|WP_000074574.1|	35.2	327	333	309	2.11e-61	197
k141_38226_23	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	31.3	243	244	233	1.85e-39	135
k141_38226_23	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.9	246	244	235	5.47e-39	134
k141_38226_23	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	31.1	241	244	239	2.63e-37	130
k141_38226_23	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.7	243	244	231	4.65e-36	126
k141_38226_23	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.5	243	244	231	4.65e-36	126
k141_38226_23	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	32.8	241	244	230	1.78e-35	125
k141_38226_23	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.1	243	244	231	2.57e-35	124
k141_38226_23	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.5	243	244	231	7.16e-35	123
k141_38226_23	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	31.7	243	244	231	1.54e-33	120
k141_38226_23	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.2	236	244	219	1.24e-32	117
k141_168537_14	SARG|gb|ABX00624.1|ARO:3002881|lmrC	29.0	552	515	550	3.17e-20	92.8
k141_168537_14	SARG|gi|446048013|ref|WP_000125868.1|	30.1	209	515	648	3.72e-18	86.7
k141_168537_14	SARG|gi|445996710|ref|WP_000074565.1|	27.6	203	515	309	8.50e-18	83.2
k141_168537_14	SARG|gi|445996719|ref|WP_000074574.1|	27.1	192	515	309	1.24e-16	79.7
k141_168537_14	SARG|gi|895736250|emb|COF64653.1|	26.6	203	515	309	1.67e-16	79.3
k141_168537_14	SARG|gi|446110087|ref|WP_000187942.1|	26.6	203	515	309	1.67e-16	79.3
k141_168537_14	SARG|gi|445996714|ref|WP_000074569.1|	26.6	203	515	309	1.67e-16	79.3
k141_168537_14	SARG|gi|895808656|emb|COR83787.1|	27.1	192	515	309	2.25e-16	79.0
k141_168537_14	SARG|gi|814314593|emb|CKF49145.1|	27.1	192	515	309	3.02e-16	78.6
k141_168537_14	SARG|gi|445996723|ref|WP_000074578.1|	26.6	192	515	309	4.07e-16	78.2
k141_168537_16	SARG|gi|896190680|ref|WP_049199932.1|	46.0	239	241	563	2.05e-60	198
k141_168537_16	SARG|YP_001477377	45.6	239	241	563	7.90e-60	196
k141_168537_16	SARG|gi|740410309|ref|WP_038243756.1|	45.6	239	241	563	1.17e-58	193
k141_168537_16	SARG|gi|1001786599|ref|WP_061324791.1|	45.2	239	241	563	1.63e-58	193
k141_168537_16	SARG|ZP_04638974	46.0	239	241	563	1.63e-58	193
k141_168537_16	SARG|YP_001401994	45.6	239	241	563	2.28e-58	192
k141_168537_16	SARG|AAS61092	45.6	239	241	563	2.28e-58	192
k141_168537_16	SARG|YP_001007250	46.0	239	241	563	3.20e-58	192
k141_168537_16	SARG|YP_001605795	45.6	239	241	562	1.26e-56	188
k141_168537_16	SARG|AAC60780	45.2	239	241	563	1.00e-54	183
k141_168537_20	SARG|AUI09862.1	49.2	132	585	287	9.90e-28	112
k141_168537_20	SARG|AJ459418.gene.p01	43.2	125	585	263	9.63e-27	108
k141_168537_20	SARG|gi|970263436|ref|WP_058647620.1|	42.4	125	585	263	1.55e-25	105
k141_168537_20	SARG|gi|486033774|ref|WP_001505252.1|	39.7	151	585	271	1.82e-25	105
k141_168537_20	SARG|gi|490067892|ref|WP_003970071.1|	39.7	151	585	271	2.48e-25	104
k141_168537_20	SARG|gi|504199703|ref|WP_014386805.1|	39.1	151	585	271	1.15e-24	102
k141_168537_20	SARG|gi|916164813|ref|WP_050960181.1|	39.1	151	585	271	1.56e-24	102
k141_168537_20	SARG|gi|487670925|ref|WP_001756235.1|	39.1	151	585	271	2.12e-24	102
k141_168537_20	SARG|DQ464881.1.gene2.p01	39.1	151	585	271	2.12e-24	102
k141_168537_20	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	39.1	151	585	271	2.12e-24	102
k141_168537_24	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.6	213	257	258	3.12e-26	102
k141_168537_24	SARG|gi|694064328|ref|WP_032410816.1|	34.2	199	257	646	1.90e-24	100
k141_168537_24	SARG|gb|CDO61516.1|ARO:3003949|efrB	33.3	177	257	362	1.63e-19	85.5
k141_168537_24	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.0	186	257	664	7.43e-18	81.6
k141_168537_24	SARG|gb|AAK76136.1|ARO:3000025|patB	30.2	182	257	588	1.44e-16	77.8
k141_168537_28	SARG|gb|AAK76136.1|ARO:3000025|patB	32.7	621	640	588	3.78e-97	308
k141_168537_28	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.9	589	640	664	3.31e-84	276
k141_168537_28	SARG|gi|764446018|ref|WP_044369325.1|	30.7	631	640	605	2.21e-76	254
k141_168537_28	SARG|gi|944009777|ref|WP_055601444.1|	30.1	622	640	628	9.91e-76	253
k141_168537_28	SARG|gi|695887424|ref|WP_032788534.1|	30.7	631	640	605	1.16e-75	252
k141_168537_28	SARG|gi|664180077|ref|WP_030714054.1|	30.6	631	640	605	1.62e-75	252
k141_168537_28	SARG|gi|663330365|ref|WP_030329892.1|	30.1	622	640	607	1.70e-75	252
k141_168537_28	SARG|gi|860594225|ref|WP_048475168.1|	30.0	627	640	620	3.14e-75	251
k141_168537_28	SARG|gi|497748188|ref|WP_010062372.1|	30.5	632	640	605	3.15e-75	251
k141_168537_28	SARG|gi|664556405|ref|WP_031071225.1|	30.8	630	640	602	4.11e-75	251
k141_168537_29	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.2	543	617	575	1.28e-94	301
k141_168537_29	SARG|gb|AAK76137.1|ARO:3000024|patA	34.2	568	617	564	2.03e-93	297
k141_168537_29	SARG|gi|926400371|ref|WP_053728483.1|	45.8	253	617	603	3.68e-61	213
k141_168537_29	SARG|gi|493394434|ref|WP_006350564.1|	39.6	321	617	602	9.60e-61	211
k141_168537_29	SARG|gi|944009777|ref|WP_055601444.1|	31.3	569	617	628	2.12e-60	211
k141_168537_29	SARG|gi|1045390184|ref|WP_065479071.1|	31.6	544	617	605	2.69e-60	210
k141_168537_29	SARG|gi|695887424|ref|WP_032788534.1|	31.6	544	617	605	5.16e-60	209
k141_168537_29	SARG|gi|748767925|ref|WP_040019608.1|	39.6	313	617	623	7.11e-60	209
k141_168537_29	SARG|gi|947982677|ref|WP_056642336.1|	45.5	253	617	626	1.43e-59	209
k141_168537_29	SARG|gi|639892676|ref|WP_024755698.1|	45.5	253	617	631	1.56e-59	209
k141_113568_2	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	21.3	310	456	397	1.11e-08	55.8
k141_113568_13	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	29.7	775	934	1033	6.51e-104	346
k141_113568_13	SARG|gb|AEY83581|ARO:3000510|mupB	29.7	775	934	1033	6.51e-104	346
k141_113568_13	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	28.7	769	934	1024	2.58e-100	336
k141_113568_13	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	28.7	769	934	1024	2.58e-100	336
k141_113568_13	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	28.7	769	934	1024	2.58e-100	336
k141_113568_13	SARG|gb|CAA53189|ARO:3000521|mupA	28.7	769	934	1024	2.58e-100	336
k141_113568_13	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	26.7	941	934	1107	8.50e-73	259
k141_113568_13	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	26.7	941	934	1107	8.50e-73	259
k141_93610_1	megares|MEG_727|Drugs|beta-lactam|Class_C_betalactamases|AMPC_1	39.9	404	427	415	7.34e-104	313
k141_93610_4	CARD|gb|AEX49906.1|ARO:3003583|basS	33.2	244	503	477	1.38e-24	105
k141_93610_5	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.7	226	240	228	4.11e-62	193
k141_93610_5	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.2	225	240	232	4.85e-59	185
k141_93610_5	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.5	227	240	231	1.34e-58	184
k141_93610_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.5	224	240	231	7.58e-58	182
k141_93610_5	CARD|gb|AAD51348.1|ARO:3003066|smeR	43.9	223	240	229	1.62e-56	179
k141_93610_5	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.7	229	240	231	2.77e-55	176
k141_93610_5	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.7	229	240	231	3.91e-55	175
k141_93610_5	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.7	229	240	231	7.83e-55	174
k141_93610_5	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	42.7	234	240	252	2.90e-54	174
k141_93610_5	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	39.7	237	240	239	7.94e-54	172
k141_234079_8	SARG|gi|694064328|ref|WP_032410816.1|	36.5	222	405	646	3.47e-36	139
k141_234079_8	SARG|gb|ADZ12699.1|ARO:3005091|RanA	35.1	188	405	258	3.68e-28	110
k141_234079_8	SARG|gi|926351744|ref|WP_053683383.1|	31.3	259	405	648	7.95e-22	96.7
k141_234079_8	SARG|gi|926376632|ref|WP_053705806.1|	30.1	259	405	620	4.42e-21	94.4
k141_234079_8	SARG|gi|917203192|ref|WP_051809904.1|	30.5	259	405	620	7.94e-21	93.6
k141_234079_8	SARG|gi|917166849|ref|WP_051773561.1|	30.9	259	405	620	7.94e-21	93.6
k141_234079_8	SARG|gi|799286378|ref|WP_045936958.1|	30.1	259	405	620	7.94e-21	93.6
k141_234079_8	SARG|gi|917127754|ref|WP_051734466.1|	30.1	259	405	620	7.94e-21	93.6
k141_234079_8	SARG|gi|926294973|ref|WP_053631154.1|	30.1	259	405	620	7.94e-21	93.6
k141_234079_8	SARG|gi|917155568|ref|WP_051762280.1|	30.9	259	405	620	1.06e-20	93.2
k141_234079_23	SARG|gi|446048013|ref|WP_000125868.1|	33.8	201	763	648	4.46e-16	81.3
k141_234079_23	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.8	236	763	582	5.84e-14	74.3
k141_234079_23	SARG|gb|AAC75271.1|ARO:3003952|yojI	31.5	213	763	547	6.12e-12	67.8
k141_234079_23	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.7	198	763	655	3.03e-09	59.3
k141_234079_23	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.7	198	763	655	3.03e-09	59.3
k141_234079_23	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.7	198	763	655	3.03e-09	59.3
k141_234079_23	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.7	198	763	655	3.03e-09	59.3
k141_234079_23	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.7	198	763	655	3.03e-09	59.3
k141_234079_23	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.7	198	763	655	3.03e-09	59.3
k141_234079_23	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.7	198	763	655	3.03e-09	59.3
k141_234079_58	SARG|gi|742409107|ref|WP_038888226.1|	38.8	317	1117	647	5.71e-54	199
k141_234079_58	SARG|gi|495004199|ref|WP_007730213.1|	38.8	317	1117	647	3.41e-53	197
k141_234079_58	SARG|gi|506220920|ref|WP_015740695.1|	38.5	317	1117	647	4.59e-53	196
k141_234079_58	SARG|gi|696420214|ref|WP_032990021.1|	39.1	317	1117	647	4.59e-53	196
k141_234079_58	SARG|gi|742384718|ref|WP_038863845.1|	38.5	317	1117	647	6.18e-53	196
k141_234079_58	SARG|gi|1020141879|ref|WP_063264839.1|	39.1	317	1117	647	6.18e-53	196
k141_234079_58	SARG|gi|490522515|ref|WP_004387938.1|	39.1	317	1117	647	6.18e-53	196
k141_234079_58	SARG|gi|803568669|ref|WP_046077412.1|	39.8	319	1117	648	6.27e-53	196
k141_234079_58	SARG|gi|446110352|ref|WP_000188207.1|	39.8	319	1117	648	6.27e-53	196
k141_234079_58	SARG|YP_002382193	39.8	319	1117	648	6.27e-53	196
k141_234079_64	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	30.5	394	525	556	1.21e-31	127
k141_4070_13	SARG|gb|AAK76136.1|ARO:3000025|patB	34.2	585	606	588	4.55e-112	346
k141_4070_13	SARG|gb|CDO61516.1|ARO:3003949|efrB	49.4	334	606	362	2.60e-104	318
k141_4070_13	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.8	514	606	664	1.26e-103	327
k141_4070_13	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.9	580	606	579	1.80e-86	279
k141_4070_13	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.3	584	606	579	1.80e-86	279
k141_4070_13	SARG|gi|944152509|ref|WP_055644808.1|	34.5	542	606	616	6.55e-85	276
k141_4070_13	SARG|gi|493394434|ref|WP_006350564.1|	33.5	538	606	602	1.29e-84	275
k141_4070_13	SARG|gi|639892676|ref|WP_024755698.1|	32.9	596	606	631	1.30e-84	276
k141_4070_13	SARG|gi|947982677|ref|WP_056642336.1|	34.8	532	606	626	1.62e-84	275
k141_4070_13	SARG|AF170880.4.gene1.p01	34.2	527	606	615	1.32e-83	273
k141_4070_14	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.8	538	755	575	4.65e-120	371
k141_4070_14	SARG|gb|AAK76137.1|ARO:3000024|patA	36.4	497	755	564	7.63e-100	318
k141_4070_14	SARG|gi|695887424|ref|WP_032788534.1|	33.5	370	755	605	5.39e-60	212
k141_4070_14	SARG|gi|764446018|ref|WP_044369325.1|	33.8	370	755	605	5.39e-60	212
k141_4070_14	SARG|gi|930482089|ref|WP_054228897.1|	34.3	370	755	599	6.64e-60	212
k141_4070_14	SARG|gi|985844137|ref|WP_060895163.1|	34.3	370	755	599	6.64e-60	212
k141_4070_14	SARG|gi|951183771|ref|WP_057661487.1|	34.1	370	755	603	7.15e-60	212
k141_4070_14	SARG|gi|664180077|ref|WP_030714054.1|	33.5	370	755	605	7.42e-60	212
k141_4070_14	SARG|gi|695891735|ref|WP_032792824.1|	33.8	370	755	603	1.35e-59	211
k141_4070_14	SARG|gi|928900436|ref|WP_053931243.1|	33.2	370	755	600	1.76e-59	211
k141_4070_28	SARG|B1LLK9	28.2	280	309	660	1.14e-20	91.3
k141_4070_28	SARG|gi|757799830|ref|WP_043017032.1|	30.7	267	309	660	2.08e-20	90.5
k141_4070_28	SARG|gi|446783041|ref|WP_000860297.1|	28.3	265	309	660	2.80e-20	90.1
k141_4070_28	SARG|B7NNT4	28.3	265	309	660	3.77e-20	89.7
k141_4070_28	SARG|gi|735685540|ref|WP_034173220.1|	28.7	265	309	660	3.77e-20	89.7
k141_4070_28	SARG|gi|486385683|ref|WP_001600222.1|	28.7	265	309	660	3.77e-20	89.7
k141_4070_28	SARG|gi|486392102|ref|WP_001603016.1|	28.7	265	309	660	3.77e-20	89.7
k141_4070_28	SARG|gi|487375894|ref|WP_001649055.1|	32.8	180	309	660	6.86e-20	89.0
k141_4070_28	SARG|gi|754613472|ref|WP_042002901.1|	28.3	265	309	660	9.25e-20	88.6
k141_4070_28	SARG|gi|487571888|ref|WP_001720337.1|	32.8	180	309	660	9.25e-20	88.6
k141_4070_36	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.7	229	230	228	9.64e-47	153
k141_4070_36	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.0	225	230	229	2.16e-39	134
k141_4070_36	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.2	235	230	231	2.18e-36	127
k141_4070_36	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.3	235	230	231	2.18e-36	127
k141_4070_36	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	30.8	234	230	232	2.24e-36	127
k141_4070_36	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	30.3	234	230	232	6.26e-36	125
k141_4070_36	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.6	235	230	231	1.70e-35	124
k141_4070_36	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	33.5	230	230	229	4.52e-35	123
k141_4070_36	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.2	235	230	231	6.70e-35	123
k141_4070_36	CARD|gb|AAG05188.1|ARO:3005068|ParR	33.6	226	230	235	1.04e-34	122
k141_128795_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	28.8	695	666	703	1.55e-73	249
k141_17487_15	SARG|gi|960873409|ref|WP_058345546.1|	32.2	245	557	648	6.46e-19	89.4
k141_17487_15	SARG|YP_001571041	32.2	245	557	648	8.56e-19	89.0
k141_17487_15	SARG|gi|555258323|ref|WP_023240896.1|	33.2	220	557	648	2.64e-18	87.4
k141_17487_15	SARG|gi|921979807|ref|WP_053271336.1|	31.4	261	557	648	6.14e-18	86.3
k141_17487_15	SARG|gi|489039527|ref|WP_002949857.1|	31.9	260	557	648	8.13e-18	85.9
k141_17487_15	SARG|gi|554689873|ref|WP_023186409.1|	30.6	268	557	648	1.08e-17	85.5
k141_17487_15	SARG|gi|446048048|ref|WP_000125903.1|	31.3	268	557	648	1.08e-17	85.5
k141_17487_15	SARG|gi|446048047|ref|WP_000125902.1|	30.6	268	557	648	1.08e-17	85.5
k141_17487_15	SARG|gi|746482713|ref|WP_039520502.1|	32.7	220	557	648	1.89e-17	84.7
k141_17487_15	SARG|gi|817602846|ref|WP_046596462.1|	34.4	212	557	648	1.89e-17	84.7
k141_17487_16	SARG|gi|950164608|ref|WP_057214157.1|	29.5	414	413	646	6.37e-37	141
k141_17487_16	SARG|gi|556279336|ref|WP_023289005.1|	29.5	414	413	646	6.37e-37	141
k141_17487_16	SARG|gi|694113305|ref|WP_032455256.1|	29.5	414	413	646	6.37e-37	141
k141_17487_16	SARG|gi|764951644|ref|WP_044521907.1|	29.5	414	413	646	6.37e-37	141
k141_17487_16	SARG|gi|1016069923|ref|WP_062914571.1|	29.5	414	413	646	6.37e-37	141
k141_17487_16	SARG|gi|927316447|ref|WP_053810605.1|	29.5	414	413	646	6.37e-37	141
k141_17487_16	SARG|gi|556468297|ref|WP_023320056.1|	29.5	414	413	646	6.37e-37	141
k141_17487_16	SARG|gi|951351507|ref|WP_057729122.1|	29.2	414	413	646	8.68e-37	140
k141_17487_16	SARG|gi|1044175355|emb|SBY84545.1|	29.2	414	413	646	1.18e-36	140
k141_17487_16	SARG|gi|647265102|ref|WP_025712979.1|	29.2	414	413	646	1.18e-36	140
k141_17487_17	SARG|gi|851922185|ref|WP_048218206.1|	50.2	219	262	648	9.24e-68	220
k141_17487_17	SARG|gi|949718947|ref|WP_057063453.1|	50.2	219	262	648	9.24e-68	220
k141_17487_17	SARG|gi|696375069|ref|WP_032949617.1|	50.2	219	262	648	9.24e-68	220
k141_17487_17	SARG|gi|489127020|ref|WP_003036815.1|	50.2	219	262	648	9.24e-68	220
k141_17487_17	SARG|gi|696368937|ref|WP_032943949.1|	50.2	219	262	648	1.29e-67	219
k141_17487_17	SARG|gi|851913025|ref|WP_048215946.1|	50.2	219	262	648	1.29e-67	219
k141_17487_17	SARG|gi|489930965|ref|WP_003834285.1|	50.2	219	262	648	1.29e-67	219
k141_17487_17	SARG|gi|803568669|ref|WP_046077412.1|	49.1	220	262	648	6.93e-67	218
k141_17487_17	SARG|gi|446110352|ref|WP_000188207.1|	49.1	220	262	648	6.93e-67	218
k141_17487_17	SARG|YP_002382193	49.1	220	262	648	6.93e-67	218
k141_17487_18	SARG|gi|857776688|emb|CRL63266.1|	23.2	332	490	358	4.46e-07	50.8
k141_17487_18	SARG|gi|857587769|emb|CRL59467.1|	23.5	327	490	369	1.42e-06	49.3
k141_17487_20	SARG|gi|1035706844|ref|WP_064548272.1|	46.8	220	227	648	3.90e-58	193
k141_17487_20	SARG|gi|736472622|ref|WP_034494292.1|	45.9	220	227	648	2.05e-57	191
k141_17487_20	SARG|gi|1035670474|ref|WP_064517458.1|	45.9	220	227	648	7.72e-57	189
k141_17487_20	SARG|gi|1035717981|ref|WP_064557480.1|	45.9	220	227	648	7.72e-57	189
k141_17487_20	SARG|Q83LR7	45.9	222	227	648	7.95e-55	184
k141_17487_20	SARG|gi|647325472|ref|WP_025760953.1|	45.9	222	227	648	7.95e-55	184
k141_17487_20	SARG|gi|647323678|ref|WP_025760497.1|	45.9	222	227	648	7.95e-55	184
k141_17487_20	SARG|gi|555268037|ref|WP_023249477.1|	45.0	222	227	648	2.14e-54	183
k141_17487_20	SARG|gi|498115003|ref|WP_010429159.1|	45.0	220	227	646	2.90e-54	182
k141_17487_20	SARG|gi|924626178|ref|WP_053530123.1|	45.0	222	227	648	2.98e-54	182
k141_234463_9	SARG|gi|654544841|ref|WP_028012549.1|	33.0	100	961	646	1.45e-07	54.3
k141_234463_9	SARG|gi|896106549|ref|WP_049136608.1|	33.0	100	961	646	1.45e-07	54.3
k141_234463_9	SARG|gi|829942568|ref|WP_047368199.1|	33.0	100	961	646	1.45e-07	54.3
k141_28964_8	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.5	233	417	359	7.00e-20	89.4
k141_28964_8	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	24.7	219	417	364	1.03e-15	77.0
k141_28964_8	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	24.7	219	417	364	1.03e-15	77.0
k141_28964_8	CARD|gb|ADM92606.1|ARO:3000549|adeS	25.5	212	417	361	1.15e-09	58.5
k141_28964_9	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.1	219	236	219	3.11e-38	131
k141_28964_9	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	31.2	231	236	233	1.77e-29	109
k141_28964_9	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.4	219	236	228	4.35e-29	108
k141_28964_9	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.6	234	236	231	6.55e-29	107
k141_28964_9	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.6	234	236	231	6.55e-29	107
k141_28964_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.1	234	236	235	7.18e-29	107
k141_28964_9	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.6	234	236	231	9.19e-29	107
k141_28964_9	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.9	232	236	232	1.85e-28	106
k141_28964_9	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.9	232	236	232	3.64e-28	105
k141_28964_9	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.6	230	236	231	4.99e-28	105
k141_209983_3	SARG|FJ872411.1.gene43.p01	29.1	378	384	702	1.27e-39	148
k141_209983_3	SARG|gi|498467693|ref|WP_010773049.1|	29.1	371	384	700	1.32e-37	142
k141_209983_3	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	30.3	337	384	700	2.44e-37	142
k141_209983_3	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	31.1	322	384	700	8.39e-37	140
k141_209983_3	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.1	339	384	700	2.11e-36	139
k141_209983_3	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	29.9	331	384	706	3.41e-35	135
k141_209983_3	SARG|JF802084.2.gene3.p01	29.7	317	384	700	6.16e-35	135
k141_209983_3	megares|MEG_7535|Drugs|Glycopeptide|VanN-type_resistance_protein|VANTN_1	29.0	286	384	656	4.24e-27	112
k141_209983_12	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	35.5	313	315	343	4.85e-60	194
k141_209983_12	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	34.8	316	315	325	7.56e-54	177
k141_209983_12	SARG|gb|AAA26793|ARO:3003748|oleC	34.5	316	315	325	2.11e-53	176
k141_209983_12	SARG|gb|AAR96051.1|ARO:3002894|otrC	30.4	316	315	351	1.18e-33	125
k141_209983_12	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	30.1	316	315	351	8.58e-33	123
k141_209983_12	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.6	226	315	258	4.06e-25	100
k141_209983_12	SARG|gb|AAK76137.1|ARO:3000024|patA	24.5	212	315	564	5.92e-13	68.2
k141_209983_12	SARG|gb|APB03219.1|ARO:3003986|TaeA	20.5	234	315	648	4.86e-07	50.1
k141_209983_12	SARG|gi|514904648|ref|WP_016630030.1|	21.8	197	315	498	4.28e-06	47.0
k141_209983_12	SARG|gi|488306124|ref|WP_002376519.1|	22.3	197	315	498	7.55e-06	46.2
k141_209983_18	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	36.3	251	244	255	5.60e-44	147
k141_209983_18	SARG|gi|803568669|ref|WP_046077412.1|	35.2	256	244	648	2.83e-37	137
k141_209983_18	SARG|gi|446110352|ref|WP_000188207.1|	35.2	256	244	648	2.83e-37	137
k141_209983_18	SARG|YP_002382193	35.2	256	244	648	2.83e-37	137
k141_209983_18	SARG|gi|803575554|ref|WP_046081557.1|	35.2	256	244	648	2.83e-37	137
k141_209983_18	SARG|gi|446110351|ref|WP_000188206.1|	35.2	256	244	648	2.83e-37	137
k141_209983_18	SARG|gi|1035670474|ref|WP_064517458.1|	34.4	256	244	648	1.89e-36	134
k141_209983_18	SARG|gi|1035717981|ref|WP_064557480.1|	34.4	256	244	648	1.89e-36	134
k141_209983_18	SARG|gi|736472622|ref|WP_034494292.1|	37.5	224	244	648	4.87e-36	133
k141_209983_18	SARG|gi|1035706844|ref|WP_064548272.1|	36.6	224	244	648	2.90e-34	128
k141_209983_29	NCBI|WP_219860712.1|1|1|blaB3SU1-1|blaB3SU1|hydrolase|2|CEPHALOSPORIN|beta-lactam|subclass_B3_metallo-beta-lactamase_B3SU1-1|AMR|beta-lactam	37.7	53	302	303	3.74e-06	46.6
k141_209983_29	SARG|gb|WP_122630831.1|ARO:3006864|CRD3-1	34.8	66	302	303	5.00e-06	46.2
k141_209983_40	SARG|gi|742378414|ref|WP_038857601.1|	39.6	240	255	647	4.12e-42	150
k141_209983_40	SARG|gi|565651791|ref|WP_023899061.1|	38.8	240	255	647	5.67e-42	150
k141_209983_40	SARG|gi|495067432|ref|WP_007792257.1|	37.9	240	255	647	7.82e-42	150
k141_209983_40	SARG|gi|695840638|ref|WP_032753940.1|	37.9	240	255	646	2.03e-41	149
k141_209983_40	SARG|gi|985815823|ref|WP_060876116.1|	37.9	240	255	646	2.80e-41	148
k141_209983_40	SARG|YP_002239469	37.9	240	255	646	2.80e-41	148
k141_209983_40	SARG|gi|556492128|ref|WP_023339842.1|	37.9	240	255	646	2.80e-41	148
k141_209983_40	SARG|gi|556337683|ref|WP_023297316.1|	38.3	240	255	646	3.85e-41	148
k141_209983_40	SARG|gi|696402390|ref|WP_032974230.1|	38.3	240	255	647	3.88e-41	148
k141_209983_40	SARG|gi|696423952|ref|WP_032993748.1|	38.3	240	255	647	3.88e-41	148
k141_209983_42	SARG|ABN80187	23.2	660	689	640	3.66e-45	170
k141_209983_42	SARG|gi|1004359922|gb|AMP42228.1|	23.1	661	689	639	4.17e-44	167
k141_209983_42	SARG|ACA23187	22.4	657	689	639	7.66e-44	166
k141_209983_42	SARG|gi|104303742|gb|ABF72138.1|	22.2	657	689	639	4.75e-43	164
k141_209983_42	SARG|CAX85496	22.2	657	689	639	8.71e-43	163
k141_209983_42	SARG|AAY62597	22.5	658	689	639	1.18e-42	162
k141_209983_42	SARG|gb|AMP42147.1|ARO:3004442|tet(W/N/W)	22.4	657	689	639	2.93e-42	161
k141_209983_42	SARG|gi|1028100281|ref|WP_063856416.1|	22.3	658	689	639	2.93e-42	161
k141_209983_42	SARG|AJ222769.gene.p01	22.3	658	689	639	3.96e-42	161
k141_209983_42	SARG|ACA23195	22.3	658	689	639	3.96e-42	161
k141_39671_10	SARG|gi|1004359922|gb|AMP42228.1|	25.9	436	606	639	7.88e-26	111
k141_39671_10	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.2	435	606	629	1.01e-25	110
k141_39671_10	ResF|tet(O/W)_4_AM889121_1	26.2	435	606	639	1.05e-25	110
k141_39671_10	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	435	606	629	4.23e-25	108
k141_39671_10	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	435	606	629	4.23e-25	108
k141_39671_10	ResF|tet(O/W)_1_AM889118_1	26.0	435	606	639	4.36e-25	108
k141_39671_10	ResF|tet(O/W)_2_AM889119_1	26.0	435	606	639	4.36e-25	108
k141_39671_10	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	435	606	629	5.63e-25	108
k141_39671_10	SARG|ABN79417	26.0	435	606	639	5.80e-25	108
k141_39671_10	SARG|AAO42740	26.0	435	606	639	5.80e-25	108
k141_74383_1	SARG|gb|AAF74725.1|ARO:3004659|Mef(En2)	25.9	112	128	401	2.90e-06	43.9
k141_74383_4	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	1.25e-90	294
k141_74383_4	SARG|gb|AKA86814|ARO:3003746|optrA	33.3	519	673	655	1.25e-90	294
k141_74383_4	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	4.78e-90	293
k141_74383_4	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	4.78e-90	293
k141_74383_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	9.35e-90	292
k141_74383_4	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	9.35e-90	292
k141_74383_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	9.35e-90	292
k141_74383_4	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	9.35e-90	292
k141_74383_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	9.35e-90	292
k141_74383_4	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	519	673	655	9.35e-90	292
k141_155333_25	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.1	692	854	1033	2.07e-27	118
k141_155333_25	SARG|gb|AEY83581|ARO:3000510|mupB	22.1	692	854	1033	2.07e-27	118
k141_155333_25	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	20.1	690	854	1024	9.45e-18	87.4
k141_155333_25	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	20.1	690	854	1024	9.45e-18	87.4
k141_155333_25	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	20.1	690	854	1024	9.45e-18	87.4
k141_155333_25	SARG|gb|CAA53189|ARO:3000521|mupA	20.1	690	854	1024	9.45e-18	87.4
k141_155333_25	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	20.3	875	854	1107	1.43e-11	67.4
k141_155333_25	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	20.3	875	854	1107	1.43e-11	67.4
k141_115525_39	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	24.1	307	735	641	1.79e-16	82.4
k141_115525_40	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	55.2	252	284	255	4.64e-99	290
k141_115525_40	SARG|gb|AAV85982.1|ARO:3000535|macB	41.7	242	284	644	3.67e-53	182
k141_115525_40	SARG|gi|696368937|ref|WP_032943949.1|	45.7	219	284	648	1.01e-50	175
k141_115525_40	SARG|gi|851913025|ref|WP_048215946.1|	45.7	219	284	648	1.01e-50	175
k141_115525_40	SARG|gi|489930965|ref|WP_003834285.1|	45.7	219	284	648	1.01e-50	175
k141_115525_40	SARG|gi|851922185|ref|WP_048218206.1|	45.2	219	284	648	1.95e-50	174
k141_115525_40	SARG|YP_002850060	45.7	219	284	648	1.95e-50	174
k141_115525_40	SARG|gi|949718947|ref|WP_057063453.1|	45.2	219	284	648	1.95e-50	174
k141_115525_40	SARG|gi|696375069|ref|WP_032949617.1|	45.2	219	284	648	1.95e-50	174
k141_115525_40	SARG|gi|489127020|ref|WP_003036815.1|	45.2	219	284	648	1.95e-50	174
k141_115525_77	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	29.7	138	243	252	1.42e-06	47.0
k141_115525_82	SARG|gb|AAK76136.1|ARO:3000025|patB	35.1	502	631	588	8.22e-97	307
k141_115525_82	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.8	486	631	664	2.86e-90	292
k141_115525_82	SARG|gi|917127754|ref|WP_051734466.1|	33.3	597	631	620	1.41e-83	273
k141_115525_82	SARG|gi|917203192|ref|WP_051809904.1|	33.5	597	631	620	2.76e-83	273
k141_115525_82	SARG|gi|799286378|ref|WP_045936958.1|	33.3	597	631	620	3.86e-83	272
k141_115525_82	SARG|gi|926294973|ref|WP_053631154.1|	33.3	597	631	620	3.86e-83	272
k141_115525_82	SARG|gi|926356413|ref|WP_053687351.1|	33.3	597	631	620	5.39e-83	272
k141_115525_82	SARG|gi|926345639|ref|WP_053677539.1|	33.3	597	631	620	5.39e-83	272
k141_115525_82	SARG|gi|926376632|ref|WP_053705806.1|	33.2	597	631	620	1.05e-82	271
k141_115525_82	SARG|gi|921231571|ref|WP_053176464.1|	33.2	599	631	620	1.47e-82	271
k141_115525_83	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.2	555	590	575	4.03e-108	335
k141_115525_83	SARG|gb|AAK76137.1|ARO:3000024|patA	33.6	569	590	564	1.13e-91	292
k141_115525_83	SARG|gi|860594225|ref|WP_048475168.1|	29.4	565	590	620	1.45e-59	208
k141_115525_83	SARG|gi|493394434|ref|WP_006350564.1|	28.5	585	590	602	3.88e-59	206
k141_115525_83	SARG|gi|648667297|ref|WP_026359044.1|	28.6	570	590	605	7.84e-59	206
k141_115525_83	SARG|gi|827013130|ref|WP_047175495.1|	28.9	570	590	603	3.84e-58	204
k141_115525_83	SARG|gi|917203192|ref|WP_051809904.1|	28.1	565	590	620	5.15e-58	204
k141_115525_83	SARG|gi|917166849|ref|WP_051773561.1|	29.4	544	590	620	5.15e-58	204
k141_115525_83	SARG|gi|655413091|ref|WP_028811890.1|	28.4	591	590	603	5.32e-58	203
k141_115525_83	SARG|gi|702897513|ref|WP_033300957.1|	28.9	571	590	601	7.11e-58	203
k141_115525_98	SARG|gi|671541568|ref|WP_031525212.1|	33.0	233	594	648	3.20e-26	112
k141_115525_98	SARG|gi|953808775|ref|WP_058042812.1|	31.0	261	594	608	4.56e-22	99.4
k141_115525_98	SARG|gi|493394434|ref|WP_006350564.1|	34.7	268	594	602	1.78e-20	94.4
k141_115525_98	SARG|gi|1011069317|ref|WP_062010695.1|	32.0	272	594	614	3.23e-20	93.6
k141_115525_98	SARG|gi|1033151784|ref|WP_064457526.1|	32.0	272	594	614	4.28e-20	93.2
k141_115525_98	SARG|gi|664304639|ref|WP_030834011.1|	32.0	272	594	614	4.28e-20	93.2
k141_115525_98	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	31.4	210	594	293	5.33e-20	89.7
k141_115525_98	SARG|gi|739906046|ref|WP_037756452.1|	32.3	254	594	620	1.01e-19	92.0
k141_115525_98	SARG|gi|817122037|ref|WP_046494699.1|	31.9	273	594	613	1.75e-19	91.3
k141_115525_98	SARG|gi|917172177|ref|WP_051778889.1|	34.5	203	594	620	1.77e-19	91.3
k141_115525_105	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	30.1	266	273	235	5.61e-32	117
k141_115525_105	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	45.3	117	273	228	1.27e-25	100
k141_115525_105	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.3	145	273	232	1.39e-25	100
k141_115525_105	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.3	144	273	231	1.90e-25	99.8
k141_115525_105	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.5	163	273	235	3.06e-22	91.3
k141_115525_105	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.0	115	273	232	2.89e-21	88.6
k141_115525_105	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.0	115	273	232	2.89e-21	88.6
k141_115525_105	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.9	110	273	232	7.75e-21	87.4
k141_115525_105	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.9	110	273	232	7.75e-21	87.4
k141_115525_105	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.4	111	273	232	7.75e-21	87.4
k141_115525_115	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.0	118	246	204	5.74e-09	53.5
k141_115525_115	CARD|gb|AAG05188.1|ARO:3005068|ParR	30.5	105	246	235	2.19e-07	49.3
k141_115525_115	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.5	109	246	228	6.95e-07	47.8
k141_195339_10	NCBI|WP_213603971.1|1|1|blaPJM-1|blaPJM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PJM-1|AMR|beta-lactam	37.9	95	233	301	1.75e-08	52.8
k141_195339_10	NCBI|WP_162338672.1|1|1|blaPJM-2|blaPJM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PJM-2|AMR|beta-lactam	37.9	95	233	301	2.37e-08	52.4
k141_195339_10	SARG|EU408347.1.gene9.p01	34.8	92	233	302	6.29e-07	48.1
k141_195339_10	NCBI|WP_256875606.1|1|1|blaNWM-1|blaNWM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_NWM-1|AMR|beta-lactam	33.6	125	233	310	6.43e-07	48.1
k141_195339_10	SARG|EU408349.1.gene1.p01	28.8	139	233	305	1.54e-06	47.0
k141_195885_10	SARG|gb|APB03219.1|ARO:3003986|TaeA	37.2	508	560	648	1.68e-107	335
k141_195885_10	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	525	560	655	3.98e-71	239
k141_195885_10	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	525	560	655	1.49e-70	238
k141_195885_10	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	525	560	655	1.49e-70	238
k141_195885_10	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	525	560	655	1.49e-70	238
k141_195885_10	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	525	560	655	1.49e-70	238
k141_195885_10	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	525	560	655	1.49e-70	238
k141_195885_10	SARG|gb|AKA86814|ARO:3003746|optrA	30.9	525	560	655	1.49e-70	238
k141_195885_10	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	525	560	655	2.08e-70	237
k141_195885_10	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	525	560	655	2.08e-70	237
k141_195885_23	SARG|gb|AYV52072.1|ARO:3002882|lmrD	24.5	233	585	664	4.73e-16	80.5
k141_195885_23	SARG|gi|921979807|ref|WP_053271336.1|	31.3	224	585	648	1.07e-15	79.3
k141_195885_23	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.9	219	585	362	4.94e-15	75.9
k141_195885_23	SARG|gb|AAK76136.1|ARO:3000025|patB	25.7	237	585	588	9.09e-15	76.3
k141_195885_36	SARG|gi|926351744|ref|WP_053683383.1|	40.7	381	602	648	1.82e-69	236
k141_195885_36	SARG|gi|748767925|ref|WP_040019608.1|	39.8	377	602	623	2.15e-69	235
k141_195885_36	SARG|gb|AAC74000.1|ARO:3003950|msbA	42.7	307	602	582	2.48e-69	234
k141_195885_36	SARG|gi|953808775|ref|WP_058042812.1|	39.9	388	602	608	4.32e-68	231
k141_195885_36	SARG|gi|860594225|ref|WP_048475168.1|	40.8	375	602	620	5.49e-68	231
k141_195885_36	SARG|gi|917229923|ref|WP_051836635.1|	39.3	400	602	620	5.49e-68	231
k141_195885_36	SARG|gi|917155568|ref|WP_051762280.1|	32.6	573	602	620	1.06e-67	230
k141_195885_36	SARG|gi|944009777|ref|WP_055601444.1|	40.3	375	602	628	1.24e-67	230
k141_195885_36	SARG|gi|917172177|ref|WP_051778889.1|	32.1	564	602	620	1.48e-67	230
k141_195885_36	SARG|gi|921231571|ref|WP_053176464.1|	32.1	564	602	620	1.48e-67	230
k141_195885_41	SARG|gi|1031822889|ref|WP_064150402.1|	42.1	221	264	646	1.57e-43	155
k141_195885_41	SARG|gi|490306253|ref|WP_004201358.1|	42.1	221	264	646	1.57e-43	155
k141_195885_41	SARG|gi|950164608|ref|WP_057214157.1|	42.1	221	264	646	1.57e-43	155
k141_195885_41	SARG|gi|895903124|ref|WP_049003730.1|	42.1	221	264	646	1.57e-43	155
k141_195885_41	SARG|gi|694113305|ref|WP_032455256.1|	42.1	221	264	646	1.57e-43	155
k141_195885_41	SARG|gi|764951644|ref|WP_044521907.1|	42.1	221	264	646	1.57e-43	155
k141_195885_41	SARG|gi|1016069923|ref|WP_062914571.1|	42.1	221	264	646	1.57e-43	155
k141_195885_41	SARG|gi|896073592|ref|WP_049116987.1|	42.1	221	264	646	1.57e-43	155
k141_195885_41	SARG|gi|896106549|ref|WP_049136608.1|	41.2	228	264	646	1.57e-43	155
k141_195885_41	SARG|gi|927316447|ref|WP_053810605.1|	42.1	221	264	646	1.57e-43	155
